Biogen (BIIB) Receives Media Impact Score of 0.17

News headlines about Biogen (NASDAQ:BIIB) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biogen earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.3604637925233 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news headlines that may have effected Accern’s rankings:

Biogen (BIIB) opened at $310.44 on Friday. The company has a market cap of $65,650.92, a P/E ratio of 14.38, a P/E/G ratio of 1.94 and a beta of 0.72. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.19 and a quick ratio of 1.90. Biogen has a 1 year low of $244.28 and a 1 year high of $348.84.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The business had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter last year, the company earned $5.19 EPS. The business’s revenue was up 4.1% on a year-over-year basis. research analysts anticipate that Biogen will post 22.03 earnings per share for the current fiscal year.

BIIB has been the topic of a number of recent research reports. Vetr cut shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 price target on the stock. in a research note on Tuesday, August 29th. ValuEngine cut shares of Biogen from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Robert W. Baird reiterated a “hold” rating and issued a $290.00 target price on shares of Biogen in a research note on Friday, August 25th. Mizuho reissued a “neutral” rating and issued a $319.00 price target (up previously from $274.00) on shares of Biogen in a report on Wednesday, September 13th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $319.00 price target (up previously from $315.00) on shares of Biogen in a report on Wednesday, July 26th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $341.89.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Insider Buying and Selling by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with's FREE daily email newsletter.

Leave a Reply